American Society of Hematology 2016 annual meeting

SummaryAt the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented.In diffuse large B ‑cell lymphoma (DLBCL), again, a more intensified treatment approach failed to improve patient survival. Moreover, and in contrast to indolent lymphoma, the use of obinutuzumab instead of rituximab (R) did not prove to be superior in DLBCL. However, data on lenalidomide maintenance, as well as da ta on novel agents in primary central nervous system lymphoma (PCNL), were presented. A survival benefit for R maintenance therapy could be shown in mantle cell lymphoma (MCL).
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research